A 5-Part Training with Self-Paced and Live-Online Components to Prepare Therapists for Work on Clairvoyant Therapeutics Clinical Research Trials

Training Program Overview

  • Part 1 provides an overview of the background and rationale for Psilocybin-Assisted Therapy and Motivational Enhancement Therapy in the treatment of AUD.

    Estimated time: 7 hours

    This portion of the training is entirely self-paced.

  • Part 2 explores ethics of psychedelic-assisted therapy and a self-reflection to explore challenges and develop ethical competence.

    Estimated time: 2 hours

    This portion of the training is entirely self-paced.

  • Part 3 is specific to the manualized treatment approach we are using in this program of research. It includes video demonstrations of two cases and a live-online Q+A session.

    Estimated time: 10-11 hours

  • Part 4 is an online self-paced training in which trainees can practice the therapist role, receive individualized feedback, and build competency.

    Estimated time: 10 hours

  • Part 5 is a skills assessment conducted by training staff.

    Estimated time: 3 hours

About Clairvoyant Therapeutics

Clairvoyant Therapeutics is a clinical stage Canadian biotech company focused on psychedelic therapy drug development for addiction.

Clairvoyant is at the forefront of a growing psychedelic therapy industry and operates under the principles of open science. Our team has a successful track record of designing and operating clinical trials and bringing new drugs to market.

We are a Life Science BC member and pending B Corporation to ensure that we meet the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose.

Psilocybin for Patients

Compelling clinical research data to date have demonstrated the transformative nature of psilocybin drug therapy to help patients suffering with substance use disorders and significant mental health conditions. 

The novel combination of staged counselling sessions and psilocybin drug administration in the presence of a trained counsellor is a paradigm shift for the substance abuse disorder and mental health treatment sector. These patients have had no significant new treatment options offered to them for a number of decades.

Clairvoyant's purpose is to provide evidence-based psychedelic therapy to help patients live healthier & enriched lives & build stronger communities.

Meet the Training Staff

Dr. Elizabeth Nielson

Chief Visionary Officer, Co-Founder and Lead Trainer

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a Site Co-Principal Investigator and therapist for an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder, and has served as a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, psilocybin-assisted treatment of treatment resistant depression, and earlier phase 2 and 3 trials of MDMA-assisted psychotherapy. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Dr. Ingmar Gorman

Chief Executive Officer, Co-Founder and Lead Trainer

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.

Dr. Jeffery Guss

Lead Trainer and Psychoanalytic Program Director

Jeffrey Guss, MD, is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, and is currently is a study therapist on studies of Psilocybin-Assisted treatment of Major Depressive Disorder and MDMA-Assisted Psychotherapy for PTSD. Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research and is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.

Aja Molinar, MA

Special Projects Coordinator

Aja Molinar received her Master’s degree in Psychology from the New School for Social Research in NYC. Her interests centered around the intersection of boredom and depression. Before pursuing graduate studies, she worked as a Child Protection Specialist for the Kansas Department of Children and Families. Aja has assisted Dr. Elizabeth Nielson and Dr. Ingmar Gorman in writing a peer-reviewed article on psychedelic harm reduction and integration. At Fluence, she assists in the development of training materials, reviews diversity scholarship applications, and serves as a liaison for enterprise-level training programs. Aja also co-leads peer groups for ethics training. Outside of work, she is a photography enthusiast, mostly working toward improving her skills in portraiture.

Dan Roberts, MD, MSW

Assistant Trainer

Dr. Dan Roberts is psychiatrist based in New York City. He is currently a lead study therapist on a clinical trial investigating the impact of psilocybin on the treatment of major depression at the New York University School of Medicine. Prior to a career transition into medicine and psychiatry, he worked as a clinical social worker, specializing in treating co-occurring disorders both in individual and group psychotherapy. Dan is also interested in meditation and contemplative practices, as well as depth psychology frameworks such as psychoanalysis and Jungian psychology.

David Gumpel, MA

Director, Training Operations

David Gumpel is an Integral Master Coach and a qualified teacher of Mindfulness-Based Stress Reduction (MBSR) through UMASS medical school. David is the co-founder of Access Mindfulness and a study coordinator for the MAPS sponsored MDMA-Assisted Therapy for the treatment of post-traumatic stress disorder study in NYC. As a coach, David teaches mindfulness to clients in private practice and to groups in corporate settings. At Fluence, David provides Mentoring and teaches MBSR courses for Certificate Program Participants. Find him online at ebcpathways.com.

Leah Gooch, Ed.M, 500RYT

Assistant Trainer

Leah Gooch teaches yoga, meditation, writing, and art in order to help individuals approach a deeper awareness of their existence. After teaching art in New York City for eight years she facilitated the creation of a mural inside of Crossroads Detention Center in Brooklyn, completed by fifteen justice-involved youth. Leah is currently a teacher and Recreation Program Leader at a correctional facility. She facilitates public and private workshops and yoga lessons and is a reiki master practitioner. Her website is fourminutesaday.org – a reference to her initial commitment to meditate for (at least!) four minutes a day.

Maisie Coburn

Program Assistant

Maisie graduated in 2020 from the University of Edinburgh with a BA in Sustainable Development and Social Anthropology. Her undergraduate dissertation explored psychedelics, ecological consciousness, and relational ontologies. She is currently pursuing an MA in Developmental Psychology at Teachers College, Columbia University. Her interests center around how our sense of self may emerge and crystallize over time, and how we may explore and design interventions to shift and expand it. At Fluence, Maisie assists in the production of program materials and written content. She lives in NYC and Woodstock, NY.

This course is only available by invitation to researchers who are training for work on clinical trials.

To register your interest in joining this program and learn about future opportunities for involvement, please email us